Business Context and Reporting Period
Kairos Pharma, LTD. (KAPA) is a clinical-stage biopharmaceutical company focused on developing therapeutics to overcome immune suppression and drug resistance in cancer. The company operates as a single reportable segment and is classified as an emerging growth company and a smaller reporting company. This summary covers the fiscal year ended December 31, 2024.
The company has no approved products and has not generated any revenue from product sales. Its operations are conducted virtually, with a pipeline of seven drug candidates targeting prostate cancer, lung cancer, breast cancer, and glioblastoma. Key assets include ENV 105 (Phase 2 in prostate cancer, Phase 1 in lung cancer) and KROS 201 (Phase 1 in glioblastoma).
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,603) | $(1,812) |
| Operating Expenses | $2,343 | $1,714 |
| Cash and Cash Equivalents (Year End) | $1,272 | $93 |
| Shareholders' Equity | $4,776 | $(2,078) |
| Accumulated Deficit | $(8,815) | $(6,212) |
Liquidity and Capital Resources: As of December 31, 2024, the company held $1.272 million in cash. Following a September 2024 IPO (net proceeds of $5.524 million) and a January 2025 PIPE offering (net proceeds of $3.145 million), management expects cash reserves to fund operations for at least 12 months from the filing date.
Material Changes vs. Prior Period
- Revenue: Remained at $0 for both periods as the company has no commercial products.
- Net Loss: Increased by approximately 44% to $2.603 million in 2024 from $1.812 million in 2023.
- Operating Expenses: Increased by $629 thousand (37%) to $2.343 million.
- R&D Expenses: Rose significantly from $82 thousand to $414 thousand, driven by the initiation of Phase 2 trials for ENV 105 in prostate cancer.
- G&A Expenses: Increased from $1.632 million to $1.929 million. This included a $481 thousand increase in consulting/contract labor, offset by a $694 thousand decrease in stock-related expenses compared to 2023.
- Other Expenses: Net other expenses increased to $260 thousand in 2024 (from $98 thousand in 2023) due to financing costs of $670 thousand and debt discount amortization, partially offset by a $599 thousand gain on the settlement of accounts payable.
- Capital Structure: The company completed its IPO in September 2024, converting outstanding convertible notes and related party debt into equity. This eliminated the convertible notes payable balance of $638 thousand recorded in 2023.
Guidance, Outlook, and Risks
Outlook and Strategy: The company plans to advance its pipeline through clinical development, specifically completing enrollment for the Phase 2 ENV 105 prostate cancer trial and the Phase 1 ENV 105 lung cancer trial. It also aims to initiate a Phase 1 trial for KROS 201. The company expects to incur significant and increasing operating losses for the foreseeable future.
Material Risks and Contingencies:
- Going Concern: The company requires substantial additional funding to meet financial needs. Failure to raise capital could force delays or cessation of development programs.
- Internal Controls: Management identified material weaknesses in internal control over financial reporting, including insufficient segregation of duties, lack of formal accounting policies, and ineffective IT general controls. Remediation efforts are underway.
- Intellectual Property: The company relies on exclusive licenses from Cedars-Sinai Medical Center and Tracon Pharmaceuticals. Failure to meet milestones or payment obligations could result in termination of these licenses.
- Regulatory Approval: There is no assurance that product candidates will obtain FDA approval. Clinical trials are expensive, time-consuming, and uncertain.
- Concentration of Ownership: CEO John S. Yu controls approximately 36% of the voting power, which may influence corporate decisions.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the ~$4.4 million in cash (post-PIPE) to fund operations through the next 12 months given the burn rate of ~$2.6 million annually.
- Internal Control Remediation: Monitor progress in addressing the disclosed material weaknesses in financial reporting and IT controls.
- Clinical Trial Progress: Track enrollment and data readouts for the ENV 105 Phase 2 prostate cancer trial and Phase 1 lung cancer trial, as these are critical value drivers.
- Licensing Obligations: Review the specific milestone payments and royalty obligations owed to Cedars-Sinai and Tracon Pharmaceuticals to ensure compliance and avoid license termination.
- Dilution Risk: Assess the impact of the Equity Line of Credit (ELOC) with Helena Global and potential future equity financings on existing shareholders.